SPIB and CD4+/CD56+ hematodermic neoplasm: In 2013, Montes-Moreno et al. (2013) reported that SPIB might be a novel immunohistochemistry marker for the diagnosis of blastic plasmacytoid dendritic cell neoplasms (BPDCN), one kind of leukemia related to pDCs (Cronin et al. 2012).